1-(N'-arylalkylaminoalkyl)aminoisoquinolines: a new class of dopamine receptor subtype

Abstract

Disclosed are compounds of the formula or the pharmaceutically acceptable salts thereof wherein the variables R5, R11, R12, R13, R1, R11, Ar, n, m and L are defined herein. These compounds are useful in treating various neuropsychochological disorders including, for example, schizophrenia, dementia, depression, anxiety, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Furthermore, compounds of this invention may be useful in treating the extrapyramidyl side effects associated with the use of conventional neuroleptic agents. The interaction of 1-(N′-(arylalkylaminoalkyl))aminoisoindole derivatives of the invention with dopamine receptor subtypes is described. This interaction results in the pharmacological activities of these compounds.

Dependencies are inferred from the claim text.